Dexamethasone

Dexamethasone 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma、Relapsed/Refractory Multiple Myeloma、Relapsed Refractory Multiple Myeloma (RRMM)、Metastatic Castration-resistant Prostate Cancer (mCRPC)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Dexamethasone 研究

• Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy

  不适用招募中加拿大NCT07176533

• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  I 期 / II 期招募中美国BrazilChile中国NCT06780111

• A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  II 期招募中美国法国意大利PolandNCT07284758

• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

  II 期招募中美国NCT05896228

• Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients

  IV 期招募中中国NCT07271849

• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

  II 期招募中意大利NCT04915248

• Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections

  不适用招募中丹麦NCT06894017

• Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery

  不适用招募中CyprusNCT07742826

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  III 期招募中美国澳大利亚加拿大新西兰NCT03959085

• Predicting Ultrasound-Guided Thoracic PVB Success in Herpetic Neuralgia

  不适用招募中EgyptNCT06761924

• Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

  III 期招募中美国NCT07772024

• The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

  II 期招募中中国NCT07065968

• Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

  II 期招募中德国NCT03993262

• Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema

  IV 期招募中法国NCT04910503

• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

  I 期 / II 期招募中美国中国NCT06609005

• Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

  II 期招募中美国NCT04991103

• A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  I 期 / II 期招募中美国Argentina澳大利亚BrazilNCT05714839

• Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

  不适用招募中中国NCT04209218

• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  III 期招募中美国澳大利亚Brazil加拿大NCT06136650

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  II 期 / III 期招募中加拿大丹麦法国GreeceNCT07570173

• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  I 期招募中美国澳大利亚中国GeorgiaNCT07477587

• Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

  II 期招募中美国NCT07201519

• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  III 期招募中美国Argentina澳大利亚奥地利NCT05623020

• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  III 期招募中美国NCT06022939

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。